SCHEMBL17654129

SCHEMBL17654129

Nc1nnc(N2CC(Nc3nnc(NC(=O)Cc4ccccc4)s3)C2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17654144 0.90 GLS (0.89) GLS
SCHEMBL26706154 0.86 GLS (0.89) GLS
SCHEMBL17664624 0.84 GLS (1.00) GLS
SCHEMBL17654173 0.84 GLS (1.00) GLS
SCHEMBL17654174 0.84 GLS (1.00) GLS
SCHEMBL17664518 0.84 GLS (1.00) GLS
SCHEMBL17654132 0.82 GLS (1.00) GLS
SCHEMBL28452921 0.82 GLS (0.90) GLS
SCHEMBL17654112 0.79 GLS (1.00) GLS
SCHEMBL17654111 0.79 GLS (1.00) GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190167648-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-06 — — US claimed
US-20170290815-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-12 — — US claimed
WO-2016054388-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-04-07 — — WO claimed
US-20250288572-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-09-18 — — US disclosed
US-20240082158-A1 COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-03-14 — — US disclosed
EP-3713569-B1 THERAPEUTIC PARTICLE COMPRISING A YAP1/WWRT1 INHIBITING AGENT AND THE GLUTAMINASE INHIBITING AGENT 2-CYCLOPROPYL-N-[5-(4-{ [5-(2-PHENYLACETAMIDO)-1,3,4-THIADIAZOL-2-YL]AMINO}PIPERIDIN-1-YL)-1,3,4-THIADIAZOL-2-YL] ACETAMIDE AND USE THEREOF FOR TREATING A PULMONARY DISEASE UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2024-03-13 — — EP disclosed
WO-2023215756-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-11-09 — — WO disclosed
WO-2023215756-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-11-09 — — WO disclosed
US-11013724-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-05-25 — — US disclosed
US-11013724-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-05-25 — — US disclosed
EP-3713569-A1 COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION University of Pittsburgh- Of the Commonwealth System of Higher Education (US) 2020-09-30 — — EP disclosed
US-20190167648-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-06 — — US disclosed
US-20190167648-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-06 — — US disclosed
WO-2019104038-A1 COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-05-31 — — WO disclosed
US-10245254-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-04-02 — — US disclosed
US-10245254-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-04-02 — — US disclosed
US-20170290815-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-12 — — US disclosed
US-20170290815-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-12 — — US disclosed
WO-2016054388-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-04-07 — — WO disclosed
WO-2016054388-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290815-A1 GLUTAMINASE INHIBITORS GLUL, ASNS, GLS GLS 3/4885
US-10245254-B2 Glutaminase inhibitors GLUL, ASNS, GLS GLS 3/4885
US-20250288572-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE GLUL, GGT1, GLS GLS 3/4885
US-20190167648-A1 GLUTAMINASE INHIBITORS GLUL, ASNS, GLS GLS 3/4885
US-11013724-B2 Glutaminase inhibitors GLUL, ASNS, GLS GLS 3/4885
US-20240082158-A1 COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION GLS2, GLS, YAP1 GLS 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback